menu
    • menu
    [{"orgOrder":0,"company":"D3 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"D3S-001","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"D3 Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Undisclosed"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"D3S-001","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"D3 Bio \/ Medicxi","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Medicxi"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"D3S-001","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"D3 Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Undisclosed"},{"orgOrder":0,"company":"D3 Bio","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"D3S-001","moa":"KRAS G12C","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"D3 Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"D3 Bio \/ Fortrea","highestDevelopmentStatusID":"7","companyTruncated":"D3 Bio \/ Fortrea"}]

    Find Clinical Drug Pipeline Developments & Deals for D3S-001

    Menu

    D3S-001

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            D3 Bio

                            China arrow
                            CTAD25
                            Not Confirmed

                            D3 Bio

                            China arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : D3S-001

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Fortrea

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Study to Assess Food Effect on Pharmacokinetics of D3S-001 in Healthy Adults

                            Details : D3S-001 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 30, 2025

                            Lead Product(s) : D3S-001

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Fortrea

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            D3 Bio

                            China arrow
                            CTAD25
                            Not Confirmed

                            D3 Bio

                            China arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : D3S-001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            D3 Bio Demonstrates Potency of D3S-001 in KRAS G12C Cancer Studies

                            Details : D3S-001 is a next-generation KRAS G12C inhibitor designed to enhance KRAS G12C target engagement. It is being evaluated for treating KRAS p.G12C Mutated non-small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 25, 2024

                            Lead Product(s) : D3S-001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            D3 Bio

                            China arrow
                            CTAD25
                            Not Confirmed

                            D3 Bio

                            China arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : D3S-001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Medicxi

                            Deal Size : $40.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Medicxi Announces $40M Investment in D3 Bio

                            Details : The financing will accelerate the development of D3 Bio's innovative pipeline, which include D3S-001 for the treatment of KRAS p.G12C Mutated non-small cell lung cancer and colorectal cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 08, 2024

                            Lead Product(s) : D3S-001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Medicxi

                            Deal Size : $40.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            D3 Bio

                            China arrow
                            CTAD25
                            Not Confirmed

                            D3 Bio

                            China arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : D3S-001

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12...

                            Details : D3S-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 08, 2022

                            Lead Product(s) : D3S-001

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth